Tag Archives | biotech portfolios and ETFs

Rayno Life Science Portfolio 2017

Rayno Life Science Portfolio 2017 YTD 6/15 Top winners YTD: BLUE up 78.9%,FMI up 121.5%,RHHBY up 13%, ABBV up 12.7%. Top Losers YTD: GILD down 9.5%, BMY down 7%. XBI up 20.9%, our top pick for aggressive portfolios. More volatile than the IBB. Portfolio mix of large cap dividend with smaller cap growth and niche […]

Continue Reading 0

Biotech Avoids Tech Wreck of June 9…Update-2 June 15

June 15-Update 2 after close…Biotechs Down with Techs-Red Screen Day Very few winners today: IBB down 0.77%, XBI down 1.36% to $71.55 near 52 week high of $73. ABBV near new highs at $70.60, BLUE up 24.7% for past month. EPZM soars 17% on EZH2 inhibitor, RXDX up 5.8% continues run on NTRK inhibitor. Trump Executive […]

Continue Reading 0

Biotechs Sink Again in Sector Shift to Technology Stocks: Update-1

6/1/17 Update at close…Biotechs Bounce off Bottom of 3 Month Trading Range IBB up 1.8% back above $290 after hitting 200 SMA bottom. XBI up 2.7% to $69.54 at SMA 50. XBI 2017 top is $72. XLV a safer play up over 1% to $76.91; above March highs and near 12 mo. highs up 11.58% […]

Continue Reading 0

Biotech Fades After ASCO Abstract Rally

Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone?  Technicals Matter  Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of the biotech ETFs. Large cap tech stocks rule. The large cap centric […]

Continue Reading 0

Biotechs Mired in a Trading Range: Breakout Delayed…Update-3

Update-3…ASCO Movers Today 5/18:  IBB up 1.28% to $292.27, XBI up 2% to $70. Nice follow through in biotech after a nasty day on 5/17 attributed to ASCO and a move away from the “Trump Trade” (industrials and materials).  Mid-caps and small caps were very strong. Large Caps: MRK up 1.35%,REGN up 2.38%. Mid Caps: […]

Continue Reading 0

Rayno Biobeat #3 2017 Biotech Breakout Coming-Update-2

Update: Big Down Day in Biotech XBI down 3% Article to follow: big movers down CELG,KITE, PBYI, TSRO, XLRN etc Update-1… 5/8/17…Biotech Sector Losing Momentum XBI down 4.3% over 5 days although still up 15.5% YTD. IBB very weak today down over 2%. NASDAQ Composite and QQQ holding near highs mainly because of strength in […]

Continue Reading 0

Biotech Sector Leads Market Early in 2017 Despite Uncertainties…Update

Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at $287.67 breaking the $290 technical level not seen since […]

Continue Reading 0

Biotech in a Doldrums: Rallies Interrupted by Geopolitics, Trump Agenda and Flight to Safety

Biotech Doldrums: Nothing to Entice Buyers Trump Agenda for Tax Reform and Deregulation Stalls Geopolitical News Curbs Market Sentiment Recent geopolitical news has created a backdrop that has discouraged investors in biotech who were already risk averse from drug pricing issues. There has been little momentum since mid-March with choppy sluggish trading. Drug stocks have […]

Continue Reading 0

Vertex (VRTX) Soars on Clinical Data and Boosts Biotech Stocks…Updates

Update…3/31/17 Performance %: March and YTD FBT  -0.83, +15.87 FBIOX  -2.43, +15.79  * Fidelity ahead of IBB in 2017 IBB   -3.05,+10.5 QQQ +1.04, +11.73 XBI   -2.82, +17.15 XLV   -1.9, +7.86 Notable Rayno Portfolio Picks %: March and YTD ABBV  +2.9,  +4.08 AMGN  -8.95, +12.22 BLUE  +7,  +47.33 FMI +13.85  +82.2 HOLX  +3.18, […]

Continue Reading 0

Biotech Stocks Sink with Broad Sell-Off on Political Realities…Updates

3/22 Update after close..Relief Rally Awaiting Tomorrow’s Vote Large Caps-mostly green with IBB up 0.54%. Mid Caps-some strength RDUS up 3.48% SGEN up 1.74 %, ,TSRO up 4.08%. Small caps XBI up 0.98%. NASDAQ up 0.48%. ========== Biotech Stocks Sink on Trump Comments Uncertainty Mounts for GOP Healthcare Plan-Fewer Patients Higher Costs? Worse Day of the Year […]

Continue Reading 0